The partners have initiated a phase I trial to evaluate LuCaFab (ITM-31), a radiolabelled a-CA XII antibody Fab fragment, for the treatment of glioblastoma. The goal is to eradicate residual tumour cells following surgery to reduce the risk of relapse.

Ascenion, technology transfer partner of Hannover Medical School (MHH), has supported the conclusion of a collaboration and licence agreement between MHH and Novo Nordisk.